


# Evermine 50 EES-1-BGM Study

## Study Highlights

- Principal Investigator: Dr. Suresh V. Patted
- This was a prospective, post-marketing, single-center study to evaluate safety and performance of the Evermine 50™ Everolimus Eluting Coronary Stent System (EES) in the treatment of patients with coronary artery disease (CAD)
- The Evermine 50 EES demonstrated favourable safety and performance with low 1-year MACE rate in real-world patients with CAD



## ❖ Study Design

A prospective, single-arm, single-center, real-world study



A total of 251 patients were enrolled



One investigational site across India



Clinical follow-up at 30 days

Clinical/Telephonic follow-up at 6-month, 12-month and 24-month

## ❖ Study Results






Figure 1: Cardiac status of study population, (%)



**Figure 2: Baseline diseased vessels characteristics of study population, (%)**



**Figure 3: Baseline lesion Characteristics of study population, (%)**

## ❖ References

1. CTRI Number: CTRI/2017/03/008173  
<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=17117&EncHid=&userName=Meril>
2. Patted SV, Patted AS, Turiya PK, Thakkar AS. Clinical Outcomes of World's Thinnest (50 µm) Strut Biodegradable Polymer Coated Everolimus-Eluting Coronary Stent System in Real-World Patients. *Cardiology Research*. 2018;9(6):370-7
3. Patted SV and Thakkar AS. 1-Year Clinical Outcomes After Percutaneous Coronary Intervention With Biodegradable Polymer Ultra-Thin Strut Everolimus-Eluting Coronary Stent System. *Journal of the American College of Cardiology*. 2019;74(13)\_Supplement/B298.